Merck, Roche Announces Distribution Agreement
News Dec 02, 2016
Merck has announced an expansion of its distribution alliance with Roche to include the polymerase chain reaction (PCR) and quantitative real-time PCR (qPCR) enzyme products of Kapa Biosystems, a company acquired by Roche in 2015. The addition of the Kapa portfolio strengthens Merck’s existing distribution relationship with Roche by providing one of the most complementary suites of high-performance tools for PCR and qPCR available in the industry.
“The alliance extension with Roche will offer our customers greater access to novel products via our world-class distribution channel,” said Udit Batra, Member of the Merck Executive Board and CEO, Life Science. “These enzymes represent a significant advantage over commercially available DNA polymerases and thus offer the potential for entirely new PCR applications.”
Under the terms of the agreement, Merck will employ its sales, marketing and e-commerce expertise and leverage the strength of its relationships with the scientific community to present and distribute Kapa PCR and quantitative PCR reagents and kits. The distribution agreement includes all geographies except the U.S., Japan and Brazil. Financial details were not disclosed.
Roche inked the global exclusive distribution agreement for its Biochemical Reagents portfolio with Sigma-Aldrich in July 2015. Following the acquisition of Sigma-Aldrich by Merck in the same year, this agreement became an important part of Merck, driving growth in its life science business and offering premier brand tools for genomics, proteomics and cell analysis.
The novel PCR enzymes offered under the expanded distribution agreement have improved tolerance to common PCR inhibitors, increased speed and specific activity, and higher fidelity. These characteristics enable higher quality results and improved workflows. Transition of Kapa’s PCR and qPCR portfolios to Merck is expected to be completed by January 1, 2017. In the interim, these products will continue to be available through existing Kapa channels.
Source: Story from Merck KGaA. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Necroptosis Pathway Implicated in Alzheimer's DiseaseNews
Researchers find first evidence that activation of the necroptosis pathway is closely linked with Alzheimer’s Disease severity.READ MORE
New England Biolabs, TTP Collaborate to Provide Services for Molecular DiagnosticsNews
New England Biolabs and TTP plc combine to offer product development services to molecular diagnostic technology developers.READ MORE